Weixin Medical Completes Nearly 100 Million RMB Series A Financing, with T-Capital as Financial Advisor
In July 2023, Weixin Medical, an innovative medical device platform for women’s health, completed a nearly 100 million RMB Series A financing. This round was led by Jinding Capital and co-invested by Taiyu Investment, with T-Capital acting as the financial advisor.
The proceeds from this round will be primarily used for product registration, advancement of clinical research, and R&D team building, further promoting the R&D, registration, and industrialization of Weixin Medical’s innovative medical device products for women’s reproductive health.
For T-Capital, this is a transaction case of providing professional financial advisory services for equity financing of innovative medical technology enterprises in the fields of medical devices and women’s health.
Transaction Overview
| Item | Information |
|---|---|
| Transaction Date | July 2023 |
| Transaction Type | Series A Financing |
| Financing Size | Nearly 100 Million RMB |
| Company | Weixin Medical |
| Company Field | Innovative Medical Devices for Women’s Health |
| Main Focus | Screening, diagnosis, treatment, rehabilitation, and medical aesthetics for women’s reproductive health |
| Lead Investor | Jinding Capital |
| Co-investor | Taiyu Investment |
| T-Capital’s Role | Financial Advisor for this round |
| Use of Proceeds | Product registration, clinical research, R&D team building |
I. Client: Weixin Medical - An Innovative Medical Device Platform for Women’s Health
Weixin Medical is a platform-based enterprise dedicated to the development of innovative products for the entire field of women’s reproductive health, including screening, diagnosis, treatment, rehabilitation, and medical aesthetics.
The company aims to provide more complete solutions for women’s health through innovative medical device products and platform capabilities.
Focusing on the clinical needs in the diagnosis and treatment of female diseases, Weixin Medical has built an innovative product platform that helps doctors reduce the burden of equipment use and further improve the efficiency of screening, diagnosis, and treatment of female diseases by integrating different products and functions.
The company’s business covers several important scenarios in women’s reproductive health, including:
- Screening for female diseases;
- Diagnosis of female diseases;
- Treatment of female diseases;
- Women’s health rehabilitation;
- Women’s medical aesthetics;
- R&D of innovative medical devices.
This platform-based positioning means that Weixin Medical is not solely focused on a single medical device, but on establishing an innovative medical device layout with multiple products and clinical application scenarios centered around women’s reproductive health.
II. Cervical Diagnosis and Treatment: Improving Screening and Treatment Efficiency with Innovative Imaging Technologies
Cervical disease screening and treatment is one of the key application areas for Weixin Medical.
In the traditional process of early cervical screening, clinicians may face issues such as time-consuming examinations, bulky equipment, complex operating procedures, and limited diagnostic automation.
In response to these clinical scenarios, Weixin Medical has developed related products using fluorescence imaging and NBI narrow-band imaging technology, aiming to complete the screening for cervical precancerous lesions in a shorter time.
On this basis, the company further combines photodynamic therapy technology to explore an integrated solution from early screening and diagnosis to treatment, and to achieve real-time monitoring of treatment effects.
This product design concept reflects Weixin Medical’s platform-based philosophy:
Connecting screening, diagnosis, and treatment through product and technology integration.
For doctors, this model helps to simplify some operating procedures; for medical institutions, it offers the opportunity to reduce the burden of equipment investment, maintenance, and management; for patients, it balances treatment benefits and costs.
III. Uterine Cavity Diagnosis and Treatment: Exploring the “Ultra-Minimally Invasive” See-and-Treat Model
In addition to cervical diagnosis and treatment, Weixin Medical is also developing innovative products for the diagnosis and treatment of uterine cavity diseases.
The company proposes an “ultra-minimally invasive” see-and-treat surgical plan for outpatient day surgery centers, and attempts to replace traditional hysteroscopy and surgical hysteroscopy with an ultra-fine disposable hysteroscopy diagnosis and treatment system.
This product concept focuses on:
- Minimally invasive;
- Simplified operating procedures;
- Single-use;
- Outpatient day surgery;
- Integrated diagnosis and treatment.
For hospitals, platform-based innovative devices can be purchased and used according to clinical needs, helping to reduce some equipment investment, maintenance, and management costs.
For doctors, the product further simplifies tools and procedures without changing the core clinical operating logic.
For patients, it focuses on the balance between diagnostic and treatment experience, treatment costs, and treatment benefits.
IV. Why did Weixin Medical attract capital attention?
Women’s health is a sub-field of healthcare with long-term clinical needs.
One of the core characteristics of Weixin Medical is its establishment of an innovative medical device platform centered on women’s reproductive health, rather than just developing a single product.
The company’s product layout covers:
Screening → Diagnosis → Treatment → Rehabilitation → Medical Aesthetics
multiple scenarios in women’s health.
This platform-based strategy helps the company to continuously expand its product portfolio based on clinical needs.
At the same time, Weixin Medical has established a team covering R&D, registration, quality management, and channel sales of medical devices, providing an organizational foundation for product R&D and industrialization.
V. Core Team with Years of Experience in the Medical Device Industry
As of this round of financing, the Weixin Medical team has nearly 30 members.
The team members cover:
- Product R&D;
- Product registration;
- Quality management;
- Channel sales;
- Medical device industrialization.
Team members have long-term experience in the medical industry, with some members having worked for companies such as Medtronic, Johnson & Johnson, Hologic, and Tigermed.
Weixin Medical’s CEO, Zhang Yang, has 18 years of experience in medical device R&D and multinational corporate management.
Zhang Yang graduated from Shanghai Jiao Tong University and has studied corporate innovation management at Stanford University.
His professional experience includes:
- General Manager of the Surgical Business Unit at MicroPort;
- Asia-Pacific R&D Director at BD;
- Senior R&D Manager at Medtronic;
- Principal Design Engineer at Johnson & Johnson.
During his career, he has participated in and led the design and development of products such as Medtronic’s microwave ablation, BD’s large-infusion indwelling needle, Johnson & Johnson’s Ethicon stapler, and MicroPort’s ECMO.
For medical device startups, R&D, registration, quality, and commercialization capabilities require long-term accumulation.
The industry experience of the Weixin Medical team provides an important foundation for the company to promote the R&D and industrialization of innovative products.
VI. Investors in this Round: Industrial Resources and Healthcare Investment Capabilities
This round of financing was led by Jinding Capital and co-invested by Taiyu Investment.
Founded in 2014, Jinding Capital is a CVC industrial investment company that has long focused on industries such as healthcare, consumption, and technology.
In the healthcare field, Jinding Capital focuses on areas such as consumer healthcare, serious medical care, and life sciences, and has long been concerned with innovative companies in the healthcare industry.
In this round of investment, Jinding Capital not only provides capital support, but also has industrial resources and doctor resources, which are expected to further support Weixin Medical’s product R&D and clinical application.
Founded in 2014, Taiyu Investment is an independent venture capital institution under Tigermed, mainly focusing on early- and growth-stage healthcare companies.
Its investment directions include:
- Medical devices;
- Biopharmaceuticals;
- CRO;
- Health food.
Therefore, the investors in this round all have a background in healthcare industry investment.
For medical device companies in the stages of product R&D, registration, and clinical research, in addition to funding, industrial resources, clinical resources, and industry experience are also of great value.
VII. Financing Proceeds will Focus on Product Registration, Clinical Research, and R&D Team Building
Weixin Medical stated that the proceeds from this round of financing will be mainly used for three aspects:
1. Advancing Product Registration
For medical device products to move from R&D to commercialization, they need to go through the corresponding registration and approval process.
The financing proceeds will support the company in further advancing the registration and certification of related products.
2. Advancing Clinical Research
For innovative medical device products that require clinical research support, the company will continue to advance related clinical research work to provide a basis for product registration and subsequent commercialization.
3. Supplementing the R&D Team
The company plans to further attract outstanding talents to join the R&D team to enhance product R&D and innovation capabilities.
Therefore, the core goal of this round of financing is not simply to expand the team size, but to invest in the path of medical device industrialization:
R&D → Clinical → Registration → Product Commercialization
VIII. T-Capital Acts as Financial Advisor for this Round
In this round of financing, T-Capital acted as the financial advisor to Weixin Medical, assisting the company in completing this round of equity financing.
For innovative medical device companies, financing not only requires capital matchmaking, but also requires a systematic presentation of the company’s:
- Technological innovation capabilities;
- Product pipeline;
- Clinical value;
- Registration progress;
- Market space;
- Commercialization path;
- Core team;
- Future development strategy
to potential investors.
The value of a financial advisor lies in helping the company translate its corporate value and capital needs into a transaction logic that investment institutions can understand and evaluate, and in promoting the financing process from investor screening and capital matchmaking to transaction negotiation and final closing.
This Series A financing of Weixin Medical is one of the representative cases of T-Capital’s services for equity financing of innovative medical device companies.
IX. T-Capital: Focusing on Capital and Strategic Consulting in the Healthcare Field
T-Capital is a consulting firm focused on the healthcare industry, providing services such as:
- Equity financing;
- Mergers and acquisitions;
- Divestitures;
- Licensing and joint ventures;
- Cross-border transactions.
T-Capital has a long-term focus on healthcare companies with technological innovation or business model breakthroughs, and is committed to discovering and creating corporate value, and helping companies connect with capital, industrial resources, and international partners.
Service areas cover:
- Emerging technologies;
- Medical devices;
- Medical diagnostics;
- High-value consumables;
- New drug R&D;
- Medical services;
- Consumer healthcare;
- Digital health.
As of the disclosure of this case, T-Capital has served more than 100 clients, with a total service amount exceeding 30 billion RMB or its equivalent in US dollars.
X. If Your Company is Looking for Financing, How Can T-Capital Help?
For healthcare companies, the core issue of financing is usually not “are there any investment institutions,” but:
How to find capital partners who truly understand the company’s track, product value, and development stage.
Especially for medical device, biopharmaceutical, medical diagnostic, and digital health companies, investors usually need to understand:
- Technical barriers;
- Clinical value;
- Product registration;
- Market space;
- Commercialization path;
- Competitive landscape;
- Core team;
- Subsequent financing needs.
T-Capital’s long-term accumulated industry experience in the healthcare industry can help companies sort out their financing strategies from both the capital market and industrial market dimensions, and connect with potential investors and industrial partners.
If your company is considering Series A, Series B, or subsequent equity financing, or hopes to find strategic investors, industrial capital, or international partners in the healthcare field, you can further communicate with the T-Capital team.
Key Transaction Information for this Case
Company: Weixin Medical
Financing Stage: Series A
Financing Size: Nearly 100 Million RMB
Financing Date: July 2023
Lead Investor: Jinding Capital
Co-investor: Taiyu Investment
Financial Advisor: T-Capital
Company Field: Innovative Medical Devices for Women’s Health
Core Focus: Screening, diagnosis, treatment, rehabilitation, and medical aesthetics for women’s reproductive health
Use of Proceeds: Product registration, clinical research, and R&D team building
About Weixin Medical
Weixin Medical is an innovative medical device platform for women’s health, dedicated to developing innovative products for the entire field of women’s reproductive health, including screening, diagnosis, treatment, rehabilitation, and medical aesthetics, to provide complete solutions for women’s health.
The company integrates different medical devices and functions through platform-based product R&D, helping doctors reduce the burden of equipment use and supporting the screening, diagnosis, and treatment of female diseases.
About T-Capital
T-Capital focuses on capital and strategic consulting in the healthcare industry, providing services such as equity financing, mergers and acquisitions, divestitures, licensing and joint ventures, and cross-border transactions.
T-Capital focuses on healthcare companies with technological or business model breakthroughs, and is committed to connecting capital, companies, industrial resources, and international partners.
If you are looking for a financing advisor, or hope to find industrial capital, strategic investors, or cross-border partners for your company, you are welcome to contact T-Capital.